A federal appeals court in Delaware refused to rehear a lawsuit over so-called skinny labels, and generic drug makers say the ruling will delay generic competition. Teva reportedly plans to appeal the case to the U.S. Supreme Court, but the company didn’t not respond to requests for confirmation. The lawsuit (case no.: 2018cvpri1976) is over Teva’s generic of the GlaxoSmithKline heart drug Coreg. Teva asked for a rehearing after the court ruled that Teva improperly promoted its generic Coreg, approved...